Related Experiment Video
Updated: Aug 12, 2026
Spatial Profiling of Protein and RNA Expression in Tissue: An Approach to Fine-Tune Virtual Microdissection
Published on: July 6, 2022
Spatial Profiling Reveals Immune Escape Pathways and Therapeutic Vulnerabilities in Prostate Cancer Bone Metastases
Katie L Owen1, Linden J Gearing2, Birunthi Niranjan3
1Peter MacCallum Cancer Centre Melbourne, Victoria Australia.
Abstract:
Prostate cancer (PCa) frequently metastasizes to bone, marking incurable disease. This progression is driven by an immunologically cold bone tumor microenvironment that fosters resistance to therapy. To define the mechanisms underlying this uniquely immunosuppressive niche, we applied spatial single cell analyses across primary tumors and metastatic sites. Bone metastases showed marked suppression of tumor-intrinsic type I interferon (IFN-I) signaling and loss of antigen presentation, features that were strongly associated with reduced bone metastasis-free survival. Tumor-intrinsic IFN-I expression correlated with memory T cell infiltration, whereas the bone myeloid compartment was enriched for protumor macrophages and showed reduced dendritic cell (DC) activation and antigen presentation. Digital spatial profiling of matched tumors revealed a broad loss of IFN-I-regulated immunostimulatory and checkpoint molecules. Notably, B7-H3, a putative negative regulator of IFN-I, was highly expressed in bone metastases and inversely associated with antigen presentation. These findings define bone-specific mechanisms of immune resistance and highlight therapeutic vulnerabilities that could inform precision therapeutic strategies for PCa.
Insights
Prostate cancer bone metastasis creates an immune-suppressive tumor microenvironment. This study reveals suppressed type I interferon (IFN-I) signaling and antigen presentation in bone metastases, offering new therapeutic targets for prostate cancer.
Area of Science:
- Immunology
- Oncology
- Cancer Biology
Background:
- Prostate cancer (PCa) commonly metastasizes to bone, leading to incurable disease.
- The bone tumor microenvironment is characterized by immune suppression, contributing to therapeutic resistance.
- Understanding these immunosuppressive mechanisms is crucial for developing effective treatments.
Purpose of the Study:
- To investigate the mechanisms driving the immunosuppressive bone tumor microenvironment in prostate cancer.
- To identify key molecular and cellular features associated with immune evasion in bone metastases.
- To uncover potential therapeutic vulnerabilities in prostate cancer bone metastasis.
Main Methods:
- Spatial single-cell analyses were performed on primary tumors and bone metastatic sites.
- Digital spatial profiling was utilized to analyze matched tumor samples.
- Immunohistochemistry and gene expression analysis were employed to assess immune cell infiltration and molecular markers.
Main Results:
- Bone metastases exhibited suppressed tumor-intrinsic type I interferon (IFN-I) signaling and impaired antigen presentation.
- Reduced IFN-I signaling and antigen presentation correlated with poorer bone metastasis-free survival.
- The bone myeloid compartment showed enrichment of protumor macrophages and reduced dendritic cell (DC) activation.
- High expression of B7-H3, a potential IFN-I inhibitor, was observed in bone metastases and inversely correlated with antigen presentation.
Conclusions:
- Bone metastasis in prostate cancer is characterized by specific immune-suppressive mechanisms, including suppressed IFN-I signaling and antigen presentation.
- These findings highlight B7-H3 as a potential therapeutic target.
- The study identifies critical vulnerabilities in the bone tumor microenvironment that could inform precision therapeutic strategies for advanced prostate cancer.
